BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib (AP24534) is a breakpoint cluster region-Abelson (BCR-ABL) inhibitor that was shown to be capable of overcoming mutation-based resistance in chronic myeloid leukemia patients (51, 52).